# Progress Note 07 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Joe Louis (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-BX002-SYN-TD
- Date: 1969-10-26
- Fictional facility: St. Posthumous Health Center
- Fictional author: Desmond Achterberg-Cole, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Fifteen-week review off the antipsychotic. **S**

## History of present illness

Mr. Louis returns five weeks after his ten-week review. He finished the aripiprazole taper three weeks ago and has had no persecutory thoughts and no trouble sleeping. He completed twelve weeks of contingency management: 22 of 24 scheduled tests were done and 21 were negative, the positive one after his single day of use; he has had no cocaine since. On his trip last month he tested at a partner clinic and had his therapy session by phone. He will continue weekly therapy and a weekly urine test for now. His home readings average 124/78 mmHg. The tax clinic reviewed his records and found nothing owed; with the social worker he has a budget and has applied for veterans' health benefits. He would like his zoster and second hepatitis B vaccines today. **S**

| Element | Detail |
|---|---|
| Cocaine | None for eight weeks |
| Contingency management | Twelve weeks completed; 21 of 22 tests negative |
| Aripiprazole | Stopped three weeks ago; no return of symptoms |
| Home blood pressure | Average 124/78 mmHg |
| Finances | Nothing owed; budget; veterans' benefits applied for |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy good; weight steady |
| Cardiovascular | Negative | No chest pain, palpitations or ankle swelling |
| Neurological | Negative | No headaches or memory lapses |
| Psychiatric | Negative | No persecutory thoughts; sleeping well; no thoughts of suicide or of harming anyone |

4 systems reviewed. **S**

## Current medications

- Naloxone 4 mg nasal spray, one spray into one nostril for a suspected opioid overdose, repeated every two to three minutes in the other nostril if needed; two-pack dispensed, with fentanyl test strips and instruction for him and anyone he lives with **S**
- Amlodipine 5 mg oral tablet, one tablet daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 126/78 mmHg; pulse 72 bpm; respirations 16/min; temperature 36.7 °C; oxygen saturation 98% on room air; weight 101.6 kg; BMI 29.1 kg/m². All vital signs are synthetic.

Sodium: 140 mmol/L; Potassium: 4.3 mmol/L; Creatinine: 1.12 mg/dL; eGFR (CKD-EPI 1964): 78 mL/min/1.73 m²; Glucose: 92 mg/dL; PHQ-9: 3; GAD-7: 4. All results are synthetic.

## Change since baseline

- Sodium: 139 mmol/L at baseline, 140 mmol/L at this visit **S**
- Potassium: 4.1 mmol/L at baseline, 4.3 mmol/L at this visit **S**
- Creatinine: 1.16 mg/dL at baseline, 1.12 mg/dL at this visit **S**
- eGFR (CKD-EPI 1964): 74 mL/min/1.73 m² at baseline, 78 mL/min/1.73 m² at this visit **S**
- Glucose: 94 mg/dL at baseline, 92 mg/dL at this visit **S**
- PHQ-9: 8 at baseline, 3 at this visit **S**
- GAD-7: 9 at baseline, 4 at this visit **S**

## Immunizations given today

- Hepatitis B vaccine (HepB-CpG), second of two doses **S**
- Recombinant zoster vaccine, first of two doses **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 126/78, pulse 72; weight 101.6 kg, BMI 29.1 |
| Cardiovascular | Regular rhythm; no murmur; no edema |
| Neurological | No abnormal movements |
| Psychiatric | Relaxed; no delusional content |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Cocaine use disorder, severe, with cocaine-induced psychotic disorder, psychosis in remission off treatment** (F14.250). No psychotic symptoms three weeks after stopping aripiprazole and eight weeks without cocaine. A return of psychosis would most likely follow renewed cocaine use, and he knows the warning signs. Safety reviewed: no thoughts of suicide or of harming anyone. **S**
   - Weekly therapy and weekly urine tests for three more months.
   - Restart treatment early if persecutory thoughts or sleeplessness return.
   - Keep naloxone and test strips at home.
2. **Hypertension on amlodipine** (I10). Clinic 126/78 and home average 124/78 mmHg: at target. Sodium 140, potassium 4.3 mmol/L, creatinine 1.12 mg/dL, eGFR 78 and glucose 92 mg/dL. **S**
   - Continue amlodipine 5 mg.
   - Basic metabolic panel, urine albumin and lipids yearly.
3. **Financial insecurity** (Z59.86). The tax review found nothing owed, and he sleeps better for knowing it. **S**
   - Social worker to follow his veterans' benefits application.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Self-management | Cocaine use since the last visit (his own account), cravings and triggers | Every visit | Completed today | No cocaine for eight weeks |
| Laboratory | Urine drug tests in contingency management, with fentanyl, and prize draws for negative results | Twice weekly for twelve weeks, then at visits | Completed today | Twelve weeks completed: 22 of 24 scheduled tests done, 21 negative; weekly tests continue |
| Examination | Psychotic symptoms, insight and sleep | Every visit | Completed today | No psychotic symptoms three weeks after stopping aripiprazole |
| Medication safety | Antipsychotic safety: weight, blood pressure, akathisia (Barnes scale) and abnormal movements (AIMS) | Weight and akathisia at every visit while on treatment; AIMS at baseline and every six months | Not indicated | Aripiprazole stopped three weeks ago; weight 101.6 kg, back near baseline; no abnormal movements |
| Laboratory | Fasting glucose or hemoglobin A1c and lipids on an antipsychotic | Baseline, at four months, then yearly | Not indicated | Off aripiprazole before the four-month check; lipids and hemoglobin A1c will be repeated yearly for his cardiovascular risk |
| Examination | Blood pressure in clinic and at home | Every visit; home readings before diagnosis and after each change | Completed today | Clinic 126/78; home average 124/78 mmHg; at target |
| Laboratory | Basic metabolic panel on antihypertensive treatment | Yearly, or after a change | Completed today | Sodium 140, potassium 4.3 mmol/L, creatinine 1.12 mg/dL, eGFR 78, glucose 92 mg/dL |
| Survey | Suicide and violence risk review, safety plan and the 988 Suicide & Crisis Lifeline | Every visit | Completed today | No thoughts of suicide or of harming anyone; 988 in his phone |
| Medication safety | Naloxone and fentanyl test strips on hand | Every visit | Completed today | Naloxone and test strips still at home |
| Survey | Depression (PHQ-9) and anxiety (GAD-7) | At baseline and every four weeks while in treatment | Completed today | PHQ-9 3, item 9 scored 0; GAD-7 4 |
| Self-management | Cognitive behavioral therapy | Weekly | Completed today | Thirteen sessions so far, one by phone while traveling |
| Self-management | Finances, social work and taxpayer services | Every visit | Completed today | Nothing owed on review; budget in place; veterans' benefits applied for |
| Self-management | Family involvement, only with his consent | Every visit | Completed today | He has chosen to tell his family about his recovery himself; no clinic contact requested |

## Goal progress

- Persecutory fears gone and six or more hours of sleep. Outcome by 1969-08-10: No persecutory beliefs by four weeks; sleeping six to seven hours. **S**
- No cocaine use, his goal, with contingency management and cognitive behavioral therapy. Outcome by 1969-10-26: No use for six weeks, one day of use at week seven reported by him, none since; 22 of 24 scheduled urine tests done, 21 negative. **S**
- Blood pressure below 130/80 mmHg. Outcome by 1969-10-26: 154/98 at intake, 146/92 at diagnosis, 126/78 on amlodipine. **S**
- A clear answer about his memory and thinking once he is well. Outcome by 1969-09-21: MoCA 25 during symptoms, 27 after ten weeks; brain MRI normal; no neurocognitive disorder. **S**
- A plan for money that lets him sleep. Outcome by 1969-10-26: Budget made with the social worker; a free tax clinic review confirmed no money owed; benefits checked. **S**

## Guideline basis

- The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder (2023), American Society of Addiction Medicine and American Academy of Addiction Psychiatry (Journal of Addiction Medicine 2024;18(1S Suppl 1):1-56)
- The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia (2020), American Psychiatric Association (American Journal of Psychiatry 2020;177(9):868-872)
- Treatment for Stimulant Use Disorders (Treatment Improvement Protocol 33, updated 2021) (2021), Substance Abuse and Mental Health Services Administration
- 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults (2025), American Heart Association and American College of Cardiology (Circulation 2025;152(11):e114-e218)
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense
- CMID: Clinical Monitoring Intelligence Database, hypertension and depression, bipolar, and mood disorders monographs (2026), Aether Forge
- Adult Immunization Schedule by Age (2026), Centers for Disease Control and Prevention

## Follow-up

- Zoster vaccine and second hepatitis B dose given today. Review in three months; second zoster dose in two to six months; second hepatitis A dose in four months. Weekly therapy and urine tests. Call the clinic or 988 at any time. **S**

